{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:03:15Z","timestamp":1791496995168,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1245\/s10434-024-15359-w","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T14:01:38Z","timestamp":1716213698000},"page":"5180-5188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer"],"prefix":"10.1245","volume":"31","author":[{"given":"Sara P.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Morgan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Abuhadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Montagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Plitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6870-3285","authenticated-orcid":false,"given":"Stephanie M.","family":"Downs-Canner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"issue":"6","key":"15359_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556\u201367.","journal-title":"N Engl J Med"},{"issue":"9","key":"15359_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321.","journal-title":"N Engl J Med"},{"key":"15359_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jss.2022.08.040","volume":"281","author":"XL Baldwin","year":"2023","unstructured":"Baldwin XL, Spanheimer PM, Downs-Canner S. A review of immune checkpoint blockade for the general surgeon. J Surg Res. 2023;281:289\u201398.","journal-title":"J Surg Res"},{"issue":"1","key":"15359_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.athoracsur.2018.02.030","volume":"106","author":"MJ Bott","year":"2018","unstructured":"Bott MJ, Cools-Lartigue J, Tan KS, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 2018;106(1):178\u201383.","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"15359_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361.","journal-title":"Nat Med"},{"key":"15359_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fonc.2017.00121","volume":"7","author":"AW Elias","year":"2017","unstructured":"Elias AW, Kasi PM, Stauffer JA, et al. The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: a retrospective study. Front Oncol. 2017;7:121.","journal-title":"Front Oncol"},{"issue":"9","key":"15359_CR7","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1245\/s10434-013-2999-1","volume":"20","author":"DE Gyorki","year":"2013","unstructured":"Gyorki DE, Yuan J, Mu Z, et al. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol. 2013;20(9):3106\u201311.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"15359_CR8","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649\u201354.","journal-title":"Nat Med"},{"issue":"7","key":"15359_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cllc.2023.08.017","volume":"24","author":"K Takada","year":"2023","unstructured":"Takada K, Takamori S, Brunetti L, et al. Impact of neoadjuvant immune checkpoint inhibitors on surgery and perioperative complications in patients with non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2023;24(7):581-590 e585.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"15359_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10549-020-06090-7","volume":"186","author":"M Al-Masri","year":"2021","unstructured":"Al-Masri M, Aljalabneh B, Al-Najjar H, et al. Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes. Breast Cancer Res Treat. 2021;186(1):7\u201313.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"15359_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0360-3016(93)90169-V","volume":"26","author":"TA Buchholz","year":"1993","unstructured":"Buchholz TA, Austin-Seymour MM, Moe RE, et al. Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys. 1993;26(1):23\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"15359_CR12","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/jso.26216","volume":"122","author":"TL Sutton","year":"2020","unstructured":"Sutton TL, Schlitt A, Gardiner SK, et al. Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival. J Surg Oncol. 2020;122(8):1761\u20139.","journal-title":"J Surg Oncol"},{"issue":"5","key":"15359_CR13","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1245\/s10434-015-5020-3","volume":"23","author":"RA Sanford","year":"2016","unstructured":"Sanford RA, Lei X, Barcenas CH, et al. Impact of time from completion of neoadjuvant chemotherapy to surgery on survival outcomes in breast cancer patients. Ann Surg Oncol. 2016;23(5):1515\u201321.","journal-title":"Ann Surg Oncol"},{"key":"15359_CR14","unstructured":"Institute NC. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. 2009."},{"issue":"8","key":"15359_CR15","doi-asserted-by":"publisher","first-page":"e002597","DOI":"10.1136\/jitc-2021-002597","volume":"9","author":"LA Emens","year":"2021","unstructured":"Emens LA, Adams S, Cimino-Mathews A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021;9(8):e002597.","journal-title":"J Immunother Cancer"},{"key":"15359_CR16","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, et al. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022;13:779691.","journal-title":"Front Immunol"},{"key":"15359_CR17","doi-asserted-by":"crossref","unstructured":"Samani A, Zhang S, Spiers L, et al. Impact of age on the toxicity of immune checkpoint inhibition. J Immunother Cancer 2020; 8(2).","DOI":"10.1136\/jitc-2020-000871"},{"issue":"8","key":"15359_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1634\/theoncologist.2016-0450","volume":"22","author":"AS Betof","year":"2017","unstructured":"Betof AS, Nipp RD, Giobbie-Hurder A, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist. 2017;22(8):963\u201371.","journal-title":"Oncologist"},{"issue":"10","key":"15359_CR19","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346\u201353.","journal-title":"JAMA Oncol"},{"issue":"1","key":"15359_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"15359_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/cancers14040955","volume":"14","author":"M Allouchery","year":"2022","unstructured":"Allouchery M, Beuvon C, Perault-Pochat MC, et al. Safety of immune checkpoint inhibitor resumption after interruption for immune-related adverse events, a narrative review. Cancers (Basel). 2022;14(4):955.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"15359_CR22","doi-asserted-by":"publisher","first-page":"e2245596","DOI":"10.1001\/jamanetworkopen.2022.45596","volume":"5","author":"AS Watson","year":"2022","unstructured":"Watson AS, Goutam S, Stukalin I, et al. Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or combination immunotherapy. JAMA Netw Open. 2022;5(12):e2245596.","journal-title":"JAMA Netw Open"},{"key":"15359_CR23","unstructured":"K\u00fcmmel, S.P., Harbeck, N., Takahashi, M., Untch, M., Boileau, J., Cortes, J., McArthur, H., Dent, R., O\u2019Shaughnessy, J., Pusztai, L., Foukakis, T., Park, Y.H., Hui, R., Cardoso, F., Denkert, C., Zhu, Y., Pan, W., Karantza, V., Fasching, P.A. Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study. The American Society of Breast Surgeons 24th Annual Meeting. Boston, MA."},{"key":"15359_CR24","doi-asserted-by":"crossref","unstructured":"K\u00fcmmel, S.P., Harbeck, N., Takahashi, M., Untch, M., Boileau, J., Cortes, J., McArthur, H., Dent, R., O\u2019Shaughnessy, J., Pusztai, L., Foukakis, T., Park, Y.H., Hui, R., Cardoso, F., Denkert, C., Zhu, Y., Pan, W., Karantza, V., Fasching, P.A. Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early tnbc: surgical outcomes from the phase 3 keynote-522 study. 18th St. Gallen International Breast Cancer Conference 2023. Vienna, Austria.","DOI":"10.1016\/S0960-9776(23)00242-4"},{"key":"15359_CR25","unstructured":"Woodfin, Y.C., Teshome, M., Kuerer, H., Hunt, K.K., Meric-Bernstam, F., Barcenas, C., Sun, S. Surgical outcomes in patients receiving pembrolizumab containing neoadjuvant systemic therapy regimens for triple-negative breast cancer. The American Society of Breast Surgeons 24th Annual Meeting. Boston, MA."},{"issue":"5","key":"15359_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA. CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309\u201332.","journal-title":"Am J Infect Control"},{"issue":"35","key":"15359_CR27","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","volume":"35","author":"L Horn","year":"2017","unstructured":"Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924\u201333.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15359_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583\u20139.","journal-title":"Ann Oncol"},{"issue":"9","key":"15359_CR29","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1097\/JTO.0b013e318228a0d8","volume":"6","author":"SA Barnett","year":"2011","unstructured":"Barnett SA, Rusch VW, Zheng J, et al. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol. 2011;6(9):1530\u20136.","journal-title":"J Thorac Oncol"},{"issue":"21","key":"15359_CR30","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"10","key":"15359_CR31","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","volume":"16","author":"BC Carthon","year":"2010","unstructured":"Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16(10):2861\u201371.","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15359-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T21:06:54Z","timestamp":1720645614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15359-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["15359"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15359-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}